Next steps

Modelling work will be completed on the impact and cost effectiveness of the programme in Tayside.
WS3 plan to analyse post treatment interviews and link to administrative databases to assess treatment impacts on service users’ general health and wellbeing, drug behaviours, and their relationships to others, including family, friends and staff.
The main work of WS5 is to conduct an evaluation of HCV TasP in PWID in England to provide essential evidence for patients, clinicians and policy-makers. This will require evidence on chronic HCV infection in PWID and intensity of HCV treatment across sites in England to determine whether HCV infections reduce more in sites with greater scale-up than in sites with less intense scale-up of HCV treatment. We will develop an appropriate design with novel statistical methods to provide unbiased estimates of whether HCV has changed over time.

WS5 will also include a qualitative aspect to follow up on the implementation and impact of the recommendations for scaling up HCV testing and treatment produced in WS3.